October 2025
HealthTech maturity index: which categories are leading?
Thomas Hagemeijer
Founder & CEO, HGM Advisory
Key takeaway
Patient solutions, CareOps, and medical diagnostics are the most mature HealthTech categories with multiple scaled companies, while clinical AI, hospital IT modernization, and digital therapeutics remain in earlier stages — our maturity index maps 13 categories to help investors and operators identify where the best risk-adjusted opportunities lie.
Patient solutions, CareOps and medical diagnostics are the most mature HealthTech categories. A maturity index mapping 13 categories from early-stage venture to maturing businesses, with 3 leading scale-ups in each.
Introducing HGM’s HealthTech Maturity Index
Not all HealthTech categories are created equal. To help investors, operators, and health system leaders navigate this landscape, HGM Advisory has developed a proprietary HealthTech Maturity Index mapping 13 categories across five levels: Nascent, Emerging, Growth, Scaling, and Mature.
The index is constructed from four weighted inputs: companies at $50M+ ARR (30%), regulatory/reimbursement clarity (20%), health system adoption rates (25%), and M&A activity (25%).
Most mature: patient solutions, CareOps, diagnostics
Patient Solutions (score: 4.5): Doctolib ($6.4B valuation), Zocdoc, and Phreesia ($400M+ revenue) lead. Benefits from straightforward ROI and low regulatory burden.
CareOps (score: 4.3): Commure ($5.5B valuation), Innovaccer ($200M+ ARR), and Abridge ($850M+ valuation) lead. Clear health system budget lines for operational efficiency.
Medical Diagnostics (score: 4.1): Tempus AI ($800M+ revenue), Paige ($200M raised), and Viz.ai (1,800+ hospitals) lead. Driven by FDA’s well-established clearance pathways.
The full maturity landscape
All 13 categories ranked by maturity score.
| Category | Score | Level | Leading Scale-Ups |
|---|---|---|---|
| Patient Solutions | 4.5 | Mature | Doctolib, Zocdoc, Phreesia |
| CareOps | 4.3 | Mature | Commure, Innovaccer, Abridge |
| Medical Diagnostics | 4.1 | Scaling | Tempus AI, Paige, Viz.ai |
| Telehealth | 3.7 | Scaling | Kry/Livi, Hims & Hers, Teladoc |
| AI Scribes | 3.5 | Growth | Abridge, Nabla, DAX Copilot |
| Digital Pharmacy | 3.3 | Growth | Alto Pharmacy, Amazon Pharmacy |
| Health Data Infra | 3.1 | Growth | Veracyte, Health Gorilla, 1upHealth |
| Mental Health Tech | 2.8 | Growth | Lyra Health, Spring Health, Headway |
| Remote Monitoring | 2.6 | Emerging | Current Health, Biofourmis, Withings |
| Clinical AI | 2.3 | Emerging | OpenEvidence, Glass Health, Regard |
| Hospital IT | 2.1 | Emerging | Rhino Health, Redox |
| Genomics | 2.0 | Emerging | Tempus AI, Color Health, Illumina |
| Digital Therapeutics | 1.8 | Nascent | Click Therapeutics, Freespira |
Strategic implications
Categories scoring 2.0-3.0 offer the best risk-adjusted returns for growth-stage investors — established product-market fit but no dominant winners yet. The window is approximately 18-24 months before consolidation.
Mature categories are ripe for AI-driven reinvention. Digital therapeutics’ position at the bottom is a warning for any category that depends on novel reimbursement frameworks.
The HealthTech landscape is not a single market — it is 13 distinct markets, each with its own dynamics. Understanding maturity is essential for investment, partnership, and procurement decisions.